Last reviewed · How we verify
Prophylactic Loperamide
At a glance
| Generic name | Prophylactic Loperamide |
|---|---|
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study of Abemaciclib (LY2835219) Plus Tamoxifen or Abemaciclib Alone in Women With Metastatic Breast Cancer (PHASE2)
- Preventive stRategy for IMMU132-relatED AEs in TNBC or Luminal Breast Cancer- PRIMED (PHASE2)
- Probiotics for Prevention of Neratinib-Induced Diarrhea in Breast Cancer Patients (NA)
- Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib (PHASE2)
- A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC (NA)
- A Trial of Perifosine in Patients With Chemo-Insensitive Sarcomas (PHASE2)
- ADAM-Afatinib Diarrhea Assessment and Management (PHASE3)
- Clinical Study to Assess Efficacy and Safety of Amiodarone in Treating Patients With Ebola. Virus Disease (EVD) in Sierra Leone. EASE (EMERGENCY Amiodarone Study Against Ebola) (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Prophylactic Loperamide CI brief — competitive landscape report
- Prophylactic Loperamide updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI